Additional trials will explore combining BNT327/PM8002 and BioNTech’s proprietary antibody-drug conjugates (“ADCs”). In June 2024, the evaluation of BNT327/PM8002 in combination with BNT325/DB-1305, a ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

Upon closing, BioNTech will gain full rights to Biotheus’ pipeline candidates and its in-house bispecific antibody drug conjugate capability. The acquisition will expand BioNTech’s footprint in China, ...

Additional trials will explore combining BNT327/PM8002 and BioNTech’s proprietary antibody-drug conjugates (“ADCs ... PD-L1-low and -negative tumors who have typically been less responsive to current ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to ...